Table 1.
CLDN 18.2 expression in gastric tumor and LN metastases
| Pathological classification | Cases (N = 262) | CLDN18.2 expression | ||||
|---|---|---|---|---|---|---|
| N | % | Any positivity | 2-sided P-value, Fisher’s Exact |
Staining intensity ≥2+ in ≥40% of cells | 2-sided P-value, Fisher’s exact |
|
| n [%] | n [%] | |||||
| Primary stomach cancer | ||||||
| All samples | 262 | 100 | 228 [87.0] | -- | 135 [51.5] | -- |
| Histologic variant (Lauren classification) | ||||||
| Diffuse | 134 | 51.1 | 119 [88.8] | 77 [57.5] | ||
| Intestinal | 59 | 22.5 | 47 [79.7] | >0.05 | 23 [39.0] | 0.019 |
| Mucinous | 7 | 2.7 | 6 [85.7] | 1 [14.3] | ||
| Othera | 10 | 3.8 | 7 [70.0] | -- | 3 [30.0] | -- |
| Missingb | 52 | 19.9 | 49 [94.2] | -- | 31 [59.6] | -- |
| Grading | ||||||
| G1/2 | 69 | 26.3 | 54 [78.3] | 0.034 | 26 [37.7] | 0.005 |
| G3 | 144 | 55.0 | 129 [89.6] | 85 [59.0] | ||
| Missingb | 49 | 18.7 | 45 [91.8] | -- | 24 [49.0] | -- |
| N stage | ||||||
| pN0 | 128 | 48.9 | 117 [91.4] | 0.044 | 66 [51.6] | >0.05 |
| pN+ | 134 | 51.2 | 111 [82.8] | 69 [51.5] | ||
| T stage | ||||||
| pT1/2 | 70 | 26.7 | 65 [92.9] | >0.05 | 35 [50.0] | >0.05 |
| pT3/4 | 192 | 73.3 | 163 [84.9] | 100 [52.1] | ||
| LN metastases | ||||||
| All samples | 135 | 100 | 108 [80.0] | -- | 61 [45.2] | -- |
Abbreviations: %, percentage of N; [%], percentage of n; G, grade; LN, lymph node; N, total number of cases; n, number among N; n/a, not applicable.
aGroup ‘Other’ includes endocrine (n = 3), hepatoid (n = 4), and neuroendocrine (n = 3) tumors.
bGroup ‘Missing’ also includes cases where a classification was not applicable or not assessable.